Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body.
17, 2015 /CNW/ - Scientists at the Centre for Addiction and Mental Health (CAMH) have discovered a promising new approach to treat multiple sclerosis (MS). In a new study, they've identified a previously unknown change in the spinal cord related to MS, and a way to alter this change ...
GLP-l receptor agonizts are another kind of new therapeutic drug for DKD [90]. GLP-1 is a hormone produced through the intestinal tract that binds to GLP-1 receptors in the pancreas, stimulating insulin production and inhibiting glucagon production in the glucose-dependent way [90]. GLP-1 ...
Laquinimod, a new oral drug for multiple sclerosis. The article discusses the findings of the clinical trials, reported elsewhere in the issue by Giancarlo Comi and others, on the drug laquinimod as a treatm... Keegan,B.,Mark,... - 《Lancet》...
the use of this drug as a first line therapy will have to be weighed up against the potential long term risks which have yet to be defined." 'A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis' is published online in the on Wednesday 20 January 2010, and in pr...
Newer drug therapies for multiple sclerosis Multiple sclerosis (MS) is a disease of unknown etiology that is felt by many to be immunologically mediated. Corticosteroids have historically been used to treat acute exacerbations of MS and remain the treatment of choice, although new... J. Carter,M...
(HealthDay)—A new pill for relapsing forms of multiple sclerosis (MS) has won approval from the U.S. Food and Drug Administration.
A new drug for multiple sclerosis can dramatically reduce the chances of a relapse or a deterioration of the condition, according to a new study from researchers at Queen Mary, University of London. The results of a major trial presented at the Annual Meeting of the American Academy of Neurolo...
the data on which the conclusions of these two studies are based have yet to be subjected to peer review.In a trial of interferon beta-1b 372 patients with relapsing and remitting disease were allocated to placebo or a low dose (1.6 MIU) or high dose (8 MIU) of the drug, which was...
(Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis. The multiple sclerosis (MS) treatment landscape in the United States has changed dramatically over the past decade. While many disease-modifying therapies ... Christine,Bell,James,...